SCYNEXIS Inc — 貸借対照表 (NASDAQ:SCYX)

Financials

総資産 102.54 M119.84 M87.81 M128.41 M90.64 M59.03 M 負債合計 79.78 M78.58 M84.58 M55.45 M35.57 M9.65 M 純資産合計 22.76 M41.26 M3.23 M72.96 M55.08 M49.38 M 負債および純資産合計 102.54 M119.84 M87.81 M128.41 M90.64 M59.03 M 有利子負債合計 —28.75 M34.39 M0—— 純負債 —-75.74 M-39.11 M-98 M——

ニュース

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics - Slideshow (NASDAQ:SCYX) 2026-04-01

Brookline Capital、バリュエーションを理由にSCYNEXIS株の目標株価を引き下げ

Brookline Capital cuts SCYNEXIS stock price target on valuation

【決算速報】サイネクシス、売上高は予想を上回り、利益は予想を上回る結果に

Scynexis Inc earnings beat by $0.12, revenue topped estimates

SCYNEXIS、SCY-247静脈内製剤治験で初の患者への投与を実施

SCYNEXIS doses first patients in SCY-247 IV formulation trial

JERSEY CITY - FDA grants fast track and QIDP designations to SCYNEXIS drug

Scynexisがナスダックから上場要件を満たすための180日間の延長を取得

Scynexis receives 180-day extension from Nasdaq to meet listing requirements

SCYNEXISが抗真菌研究に年間700万ドルの助成金を受領

SCYNEXIS receives $7 million annual grant for antifungal research